Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 286

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Endometrial cancer

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia+1

Not recruiting

Study of MP0533 for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Using Sodium Dihydrogen Phosphate Dihydrate, Polysorbate 20, and Sodium Chloride

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Molecular Partners AG

Hodgkin's disease

Not recruiting

Study of Brentuximab Vedotin, Doxorubicin Hydrochloride, and Dacarbazine for Patients with Untreated Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Haemophagocytic lymphohistiocytosis

Not recruiting

Study on Ruxolitinib and Drug Combination for Critically Ill Adults with Acquired Hemophagocytic Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Assistance Publique Hopitaux De Paris

Breast cancer metastatic+2

Not recruiting

Study of Patritumab Deruxtecan for Patients with Brain Metastases from Advanced Breast or Lung Cancer and Leptomeningeal Disease from Solid Tumors

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Medica Scientia Innovation Research S.L.

Non-small cell lung cancer

Not recruiting

Study of Abemaciclib and Erlotinib for Patients with Stage IV Non-Small Cell Lung Cancer with KRAS Mutation After Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Diffuse large B-cell lymphoma refractory

Not recruiting

Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Neoplasm malignant

Not recruiting

Study of Volrustomig for Patients with Advanced Solid Tumors with Mature Tertiary Lymphoid Structures

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Volrustomig
  • Sponsor:Institut Bergonie

Glioblastoma multiforme

Not recruiting

Study on LSTA1 and Temozolomide for Patients with Newly Diagnosed Glioblastoma Multiforme

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Lsta1
  • Sponsor:Tartu University Hospital

Cholangiocarcinoma

Not recruiting

Study of Futibatinib for Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Futibatinib
  • Sponsor:Taiho Oncology Inc.

Oesophageal adenocarcinoma

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced Esophagogastric Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.